FDA to again decide on OTC switch for Plan B contraceptive

Share this article:

The FDA may decide as soon as this week on whether pharmacies can sell the Barr Pharmaceuticals' emergency contraceptive, Plan B, without a prescription to women age 16 and older, a Wall Street Journal report said.
Last May, the FDA rejected non-prescription sales of emergency contraceptives.
At the time, the FDA told Barr it could submit more data on girls under 16 years old or it could revise its application to market the drug only to females over 16. If Barr chooses the latter, it would have to submit information on how to make the age restriction work. In July, Barr again applied for approval. The company now proposes that drug stores check customers' ages to be certain that buyers are at least 16, an approach the FDA hasn't approved before. Younger teenagers could continue to get the drug with a doctor' s prescription.  
Preparing for an OTC switch, Barr has been working with IQ Design in New York on a campaign to promote a better understanding of the drug.
A limited number of states already offer the drug without a prescription – Alaska, California, Hawaii, Maine, New Mexico and Washington.

 

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.